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Introduction
Acquired brain injury, including stroke and traumatic brain injury 
(TBI), inflicts traumatic, ischemic or hemorrhagic brain insults and is 
the major contributor to death and persistent disabilities worldwide 
[1,2].  Currently, most therapies for brain injury treatments are designed 
to pharmacologically modify disease symptoms but do not promote 
neural tissue repair or restoration of severed neural networking.  There 
is a great need to develop interventions that are able to address multiple 
pathological events post-injury and promote fuller structural and 
functional restoration.  Biodegradable scaffold-facilitated cell therapy 
is a promising approach to modify the injury environment, promote 
cell replacement, stimulate endogenous regeneration mechanisms and 
provide a temporary scaffold to guide the behavior of transplant and 
endogenous cells.  Collagen-based scaffold is an attractive candidate 
for cell delivery in the brain due to its biocompatibility and ability to 
provide a three-dimensional (3D) environment that mimics the natural 
extracellular matrix (ECM).  In this review, we will first describe the 
tissue response of the brain towards injuries and the objectives of 
collagen-based cell therapy.  Then, properties and design considerations 
of collagen-based scaffolds will be illustrated, followed by discussion 
on the current developments of these scaffolds in conveying different 
sources of cells.  Lastly, conclusions and perspectives are presented for 
future work in collagen-based cell transplantation for treating brain 
disorder.
Post-injury Response of the Brain
After initial brain insult, a series of secondary injury events 
including inflammation, edema, excitotoxicity and increased free 
radicals follows causing further neuronal death [3-5] (Figure 1). 
This leads to expansion of cell death zone in the surrounding brain 
tissues and formation of glial scars mediated by activated astrocytes 
and microglia.  Although glial scars can minimize secondary damage 
around the zone of necrotic cell death, clean debris at the injury site 
and protect the uninjured tissue, they contain axonal growth inhibitory 
factors such as chondroitin sulfate proteoglycan and myelin-associated 
glycoproteins that limit neuroregeneration.  On the other hand, due 
to the presence of endogenous neural progenitor cells (NPCs), the 
adult brain has plasticity and potential to partially restore its function 
in response to stroke and trauma [6].  These cells can proliferate and 
migrate to the injury regions, express growth factors and potentially 
replace loss tissue by differentiating into neurons and glial cells [5,7]. 
However, these endogenous mechanisms are often inadequate to fully 
restore loss structures and functions.  Moreover, the loss of ECM in the 
cystic cavities within the brain parenchyma fails to provide the scaffold 
needed for neuroblasts migration [8].  This limits tissue regeneration 
within the lesion.  Strategies that support regeneration or replacement 
of the loss tissue as well as external neurotrophic and neuroregenerative 
stimulations are needed.
Scaffold-facilitated Cell Therapy for Brain Injuries
Scaffold-facilitated cell therapy offers a multifaceted approach to 
tackle the complex injury events following brain injuries.  It integrates 
the merits of cell, biomaterial scaffolds and neuroactive factor therapy. 
Cells are able to respond dynamically to the local temporal and spatial 
cues, interact continuously with the surrounding tissue and act on 
multiple mechanisms simultaneously.  However, transplanted cell 
survival is often hindered by the lack of oxygen, nutrition, trophic factors 
and structural support at the site of injury [9-12].  Also, post-injury 
excitotoxicity and inflammatory mechanisms, immunological rejection 
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and mechanical damages cause transplanted cell loss.  Biomaterials are 
therefore applied to promote cell survival and functioning, facilitate 
implantation and augment performance of cell-based therapies in the 
central nervous system (CNS) and peripheral nervous system (PNS) 
[13].  Since the ultimate goals of cell-based therapies for the injured 
brain are cell replacement and tissue regeneration, biodegradable 
materials are more attractive than non-biodegradable ones for cell 
transplantation purposes.  
Collagen is one of the most extensively used ECM components in 
neural tissue engineering (Figure 2).  Collagen constitutes the greatest 
quantity of the total proteins in the human body, and is the major 
composition of ECM. Collagen-based scaffolds offer a permissive, 
generally non-immunogenic, biocompatible, biodegradable and 
biomimetic 3D environment for cell survival, attachment, proliferation, 
and differentiation.  It has been widely applied in clinical and preclinical 
studies of neural injury and degenerative conditions of the CNS and 
Figure 1: Response of brain tissue to injury and regeneration barriers.
Figure 2: Advantages of collagen scaffolds for the injured brain.
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PNS [14-34].  For brain injury applications, collagen scaffolds have 
been applied as cell carriers for implantation in animal studies or as 
culture platforms to study interactions between various stem cells or 
neural cells in 3D biomimetic environments.  Collagen scaffolds can 
be produced by top-down or bottom-up approach [35].  Top-down 
approach comprises of decellularizing extracellular collagenous 
tissues while preserving its native architecture.  This type of scaffold 
consists not only of collagen but also a combination of structural 
and functional molecules present in the ECM, including proteins, 
proteoglycans, glycosaminoglycans, glycoproteins and other small 
molecules.  Since decellularized ECM scaffolds can be sourced from 
a variety of tissues and mammals, there exist significant differences 
in structure, composition and characteristics between these scaffolds. 
For bottom-up approach, scaffolds are produced by reconstitution of 
collagen molecules into their native fibrillar structure.  These molecules 
are obtained from broken down collagenous tissues.  In this review, we 
will focus on the in vitro and in vivo cell delivery applications of the 
latter type of collagen scaffolds. 
Collagen-based Scaffolds
Structure and types of collagen used for brain tissue 
engineering
Up to date, 29 different genetic types of collagen have been 
identified.  All collagens in the family are modular proteins consisting 
of three polypeptide α chain with at least one stretch of triple helix. 
The non-triple helical regions can either be short or large structural 
domains [36].  Homotrimers or heterotrimers formed from 25 different 
conformations of α chain give rise to different types of collagen with 
varying size, function and tissue distribution.  Based on their structure 
and supramolecular organization, collagen can be classified into 
fibril-forming collagens, fibril-associated collagens, network-forming 
collagens, anchoring fibrils, transmembrane collagens, basement 
membrane collagens and others with unique functions [36-38]. 
Fibril-forming collagens include type I, II, III, V, XI, XXIV, and 
XXVII.  Type I collagen is the most abundant and well-studied collagen, 
accounting for 25% of the dry protein in mammals and forming more 
than 90% of the organic mass of bone [37].  It is also the major collagen 
of tendons, skin, ligaments, cornea, and many interstitial connective 
tissues with the exception of very few tissues such as hyaline cartilage, 
brain, and vitreous body.  It functions to provide structural strength 
within tissues and to form a framework for other ECM components 
to interact [39].  Type I scaffold serves as a golden standard in tissue 
engineering [40].  Although the ECM of CNS tissue contains relatively 
little fibrous collagen and the brain normally expresses type IV collagen 
only, collagen type I is a better scaffold candidate than type IV for brain 
applications.  Collagen type IV is the main ECM secreted by fibroblasts 
following trauma and has shown to induce scar formation and inhibit 
axonal regeneration [41].  In contrast, collagen type I has been applied 
as scaffolds or fillers of non-biodegradable implants for cell delivery 
in animal models of TBI, Huntington’s disease (HD), Alzheimer’s 
disease (AD) and Parkinson’s disease (PD) with good biocompatibility 
[14-16,25-30].  Most reports of scaffolds for brain injury applications 
employed type I collagen.
Cell-collagen interactions
Collagen is an excellent attachment substrate for cells.  Cells can 
bind to collagen directly or indirectly.  Various cell surface collagen 
binding proteins or collagen receptors are able to recognize specific 
peptide sequence of collagen molecules, such as GPO  (Gly-Pro-Hyp) 
and GFO (Gly-Phe-Hyp) motifs, and form direct interactions [40]. 
Indirect cell-collagen interactions can be formed in the presence of 
molecules that carry integrin and collagen binding motifs, such as the 
RGD (Arg-Gly-Asp) motif or similar sequences.  Fibronectin, decorin 
and laminin are mediators of indirect collagen-cell interaction.  
Fibril-forming collagen can self-assemble into fibrils at neutral 
pH and physiological temperature [42].  Fibrils formed in vitro have 
similar morphologies and characteristic “D” periodicity with those 
observed in vivo [43,44].  In the presence of cells, spontaneous collagen 
hydrogel contraction occurs, contracting the gel and yielding scaffolds 
with higher density, increased strength and stiffness [35].  Collagen 
degradation in vivo is mediated by human collagenases secreted 
from cells, mainly matrix metalloproteinase.  Different collagenases 
have different rates of collagen hydrolysis.  The extent of changes in 
mechanical and degradation properties of collagen scaffolds differs 
based on various factors, such as cell type, cell density, collagen 
concentration and culture conditions [35].
Scaffold design considerations
Various designs of collagen scaffolds have been explored for 
brain tissue engineering.  Common forms include hydrogel, fibrous 
scaffolds, and porous scaffolds with foam, sponge and dehydrated 
matrix.  Depending on the form of scaffold used, cells, neuroactive 
agents and other biomaterials can be incorporated during or after 
scaffold fabrication.  Manufacturing techniques of collagen scaffolds 
are discussed in [45].
Stem cells and neural cells are highly responsive to physical, 
biochemical and electrical cues present in their microenvironment 
during growth, development and regeneration stages. To maximize the 
therapeutic outcomes, properties of collagen-based scaffolds should be 
optimized to recreate the spatial and temporal presentation of these 
cues. Features that are biologically relevant can be readily incorporated 
into the scaffolds.  Functionalization of collagen scaffolds can potentially 
modulate the local injury environment and influence the function of 
transplanted and endogenous cells.  Local modulations encourage cell 
survival and tissue regeneration by neutralizing local inhibitory signals, 
reducing inflammation and slowing scar formation.  In response to the 
cues, cell functions such as attachment, migration, proliferation, gene 
expressions, differentiation and growth in vivo can be better controlled. 
Depending on the intended application of the implants, these signals 
can be applied in an isotropic or anisotropic manner.  
Physical properties of a collagen-based scaffold, including their 
mechanical and topographical characteristics, have great influences on 
cell behavior, fate and functioning [46,47].  Examples of mechanical 
cues are stiffness [48], porosity [49], viscoelasticity, and topographical 
features include surface patterning, alignment, geometry and 
structure [46,50-52]. Scaffolds should be designed to have comparable 
mechanical strength with brain tissue. This enables the implant to 
resist physiological loads and mechanical stresses from neighboring 
tissues without collapsing or losing its shape [53]. Before degradation, 
the temporary scaffold should provide mechanical support in the 
lesion, allowing the survival, proliferation and differentiation of the 
transplanted cells and initial native tissue synthesis, which may take 
up to several weeks [12]. Also, culturing seeded scaffolds in vitro in 
bioreactors are applied to enhance cell survival and differentiation in 
some studies [54].   
Collagen scaffolds can also be modified through incorporating 
soluble and insoluble biochemical cues.  Soluble biochemical cues 
include diffusible signals such as neurotrophic factors, cytokines and 
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drugs that influence cell behavior and modulate the host environment 
[55].  Modifying collagen scaffolds with insoluble factors like other 
ECM molecules [16,56], immobilized neurotrophic factors or drugs 
[57], and engineered materials with biomimetic or mechanical features 
[52,58,59] can potentially improve mechanical strength and provide 
prolonged drug delivery and stimulation to cells.  However, it is 
important to ensure that the immobilization process does not affect the 
efficacy and bioactivity of the drug [60].    
Moreover, electrical stimulation can be applied to influence cell 
behavior.  Electroactive conducting polymers like carbon nanotubes 
help improving cell survival, proliferation, differentiation as well 
as neurite extension, axonal regeneration and functional recovery 
[48,61,62].  
In short, collagen-based scaffolds offer a flexible platform for 
creating interactive and instructive cell-carrying scaffolds.
Cell-based Therapy with Collagen-based Scaffolds
Cell transplantation offers the potential to treat brain injuries, 
largely because it can exert multiple mechanisms of treatment in a 
sustained fashion and transplanted cells may interact with the local 
environment [1]. Much focus have been placed on the transplantation 
of stems cells, which have the ability to renew themselves continuously 
and can differentiate into many cell types [63]. Mesenchymal stem 
cells (MSCs) and neural stem/progenitor cells (NSPCs) are the most 
studied cell types in collagen-based cell delivery in animal models 
(Table 1).  In vitro cell culture systems for embryonic stem cells (ESCs), 
induced pluripotent stem cells (iPSCs) and other neural cells have been 
developed and investigated to gain better understanding of the cell-
matrix interactions for potential application in brain tissue engineering. 
Functionalization with physical, biochemical or electrical cues are 
applied in some studies to increase the therapeutic efficacies of these 
systems.
Mesenchymal Stem Cells (MSCs)
MSCs are multipotent stem cells that are often utilized in collagen-
based brain tissue engineering.  Besides differentiating into mesenchymal 
tissues, MSCs have shown greater plasticity in transdifferentiating into 
several lineage pathways, yielding epithelial, endothelial, and neuronal 
cells [64,65].  MSCs are procured from various stem cell niches in 
adult and neonatal tissue [66-68].  Sources of adult tissue include bone 
marrow, which is the primary source, adipose tissue, peripheral blood 
and tooth pulp.  As for neonatal tissue, MSCs are obtained from birth-
associated tissues such as amnion, placenta, umbilical cord, and fresh 
or banked human umbilical cord blood.  In the following discussion, we 
would use MSC as a general acronym of these cell populations.  
MSC is an attractive cell candidate because it is relatively easy 
to obtain, expand, and manipulate in vitro [69].  MSCs are less 
immunogenic; they can be used as an autologous or allogeneic cell 
source [1], with low tumorigenicity and fewer ethical problems 
than ESCs and stem cells of a fetal origin [11,65,70].  Based on the 
expression of a complex set of factors, MSCs support neuroprotection 
and neuroregeneration of the brain through multiple mechanisms 
[1,63,71].  These factors include soluble signals, such as cytokines and 
growth factors, and insoluble factors like ECM components.  Upon 
MSC transplantation, reduction in inflammation, immunomodulation, 
protection of surrounding brain cells, and also stimulation of host 
angiogenesis, neurogenesis and synaptogenesis can be achieved.  In 
addition, a low percentage of MSCs may transdifferentiate into neural 
cells in vivo and replace loss neural tissue [72,73].  Several phase I/II 
clinical trials associated with brain injuries, including stroke, cerebral 
palsy and pediatric TBI, using genetically modified, autologous or 
allogeneic bone marrow stromal stem cells, or umbilical cord derived 
cells have been conducted [63].  Safety of MSC application for human 
brain is demonstrated in clinical trials involving TBI [74] and PD [75]. 
Collagen-based scaffolds magnify the therapeutic effects of MSCs 
in culture conditions and animal models.  Using positron emission 
tomography imaging, Guan et al. showed that after 12 hours of surgery, 
collagen scaffold-facilitated delivery of human MSCs (hMSCs) into 
the lesion of TBI rats resulted in better cell retention and minimized 
diffusion to non-specific organs when compared to direct injection 
Cell type Origin Animal and disease model Functionalization(s) or special feature(s) Results Ref.
i. MSC
Human TBI rat
Better MSC migration, survival and concentration.  Enhanced tPA and 
VEGF levels and reduced Nogo-A and neurocan levels in host tissue. 
Higher axonal, synaptic and vascular density at the boundary zone. 




Improved MSC retention with minimized diffusion to non-specific organs. 
Enhanced MSC transdifferentiation into neural lineage with neurite 
outgrowth.  Improved brain metabolism, spatial learning and sensorimotor 
function.
[11]
Rat TBI rat Absence of gliosis within scaffold.  Enhanced MSC transdifferentiation into nerve and vascular endothelial cells. [73]
Human PBI rat In situ gelling scaffold
Better retention of brain tissue and improved motor functions.  MSCs 
migrated into the surrounding tissue while activated native NSPCs and 
astrocytes infiltrated into the retained tissue.
[12]
Rat Healthy rat
- In situ gelling scaffold
- Collagen and poly(ethylene glycol) ether 
tetrasuccinimidyl glutarate scaffold with GDNF 
over-expressing MSCs
GDNF detectable surround the graft site with diminished microglia and 
astrocytes recruitments in the brain. [59]
ii. NSPC
Rat PBI rat NSPCs migrated into surrounding brain and differentiated into astrocytes, endothelial cells, oligodendrocytes and possibly macrophages. [88]
Mouse TBI mouse Collagen and laminin/fibronectin scaffold
Improved cognitive function.
Enhanced NSPC survival and distribution.
Collagen-laminin carriers showed better results than the fibronectin group.
[16]
GDNF: Glial Cell-derived Neurotrophic Factor; TBI: Traumatic Brain Injury; tPA: Tissue Plasminogen Activator; PBI: Penetrating Brain Injury; MSCs: Mesenchymal Stem 
Cells; NSPCs: Neural Stem/Progenitor Cells; VEGF: Vascular Endothelial Growth Factor.
Table 1: Collagen-based cell transplantation applied in animal models of brain injury.
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[11]. In vitro gene expression analysis revealed that in the presence 
of collagen scaffolds, expressions of angiogenesis, neurogenesis, and 
signal transduction genes, including VEGFA, TGFB2, NOTCH4, 
MDK, BCL2, and BIRC5, were upregulated in hMSCs [76]. TBI rats 
receiving collagen-MSC implants seven days post-injury showed better 
spatial learning and motor-sensory function [76,77]. Analysis of the 
brain tissues at the lesion boundary zone of these animals further 
revealed the therapeutic effects of MSC-collagen exerted on the 
surrounding brain tissue.  In the presence of collagen scaffolds, hMSCs 
enhanced the activity of tissue plasminogen activator (tPA) released by 
CNS neurons and endothelial one week post-implantation [77]. tPA 
functions to activate plasmin, which is involved in the activation of 
various neurotrophic factors in the CNS and in synaptic remodeling. 
Also, compared to transplanting hMSCs alone, cell-collagen group 
showed a higher vascular endothelial growth factor (VEGF) expression 
in astrocytes [76] and lower levels of growth-inhibitory molecules, 
including Nogo-A expression in oligodendrocytes [78] and neurocan 
from reactive astrocytes [79], at the lesion boundary zone. Homing 
response of MSCs was observed one week after implantation with 
cell migration towards the boundary zone of the collagen scaffold 
[11,77]. Enhanced axonal density [78] and synaptic density [79] in the 
lesion boundary zone in TBI rats indicated that collagen was able to 
enhance the effect of hMSCs on axonal plasticity.  However, the lesion 
volume was not significantly reduced after one week of implantation, 
which indicated that more time was probably needed to achieve 
tissue reconstruction [76]. After one month of implantation, rodents 
with cell-collagen implants showed higher MSC migration, survival 
and concentration in the lesion boundary zone than collagen-alone 
or intracerebral/intravenous injected hMSC-alone controls [80]. 
Moreover, reduced lesion volume along with higher vascular density in 
the lesion boundary zone and hippocampus were reported [11,14,80]. 
Guan et al. also reported improved neurite outgrowth and brain 
metabolism in cell-collagen implanted TBI rats than controls with cells 
or scaffolds alone [11]. Nakata et al. showed there was an absence of 
gliosis after one month of implantation when TBI rats were treated with 
collagen-implants, either with or without MSCs [73]. Improved spatial 
learning and sensorimotor functional outcomes are reported in these 
studies [11,14,80].
Enhanced transdifferentiation of MSCs in collagen scaffolds 
has been reported.  Neural differentiation and neurite outgrowth 
were detected in TBI rats receiving hMSCs one week after device 
implantation [11]. In another study, some of the collagen-delivered 
cells differentiated into nerve and vascular endothelial cells one month 
after implantation, a feature not observed in TBI rats receiving scaffolds 
alone [73]. However, some studies observed structural and functional 
rescue even when no neuronal differentiation was detected [12].  
In order to minimize the invasiveness of the scaffold implantation 
surgery and maximize scaffold conformation to the irregular lesion, 
in situ gelation platforms for MSC delivery have been applied.  Chen 
et al. injected hMSCs in liquefied collagen matrix into the injury tract 
of penetrating ballistic-like brain injury rats immediately after the 
injury induction and showed better retention of brain tissue along 
with improved motor functions [12].  Migration of transplanted MSCs 
into the subventricular zone and the corpus callosum, along with 
infiltration of native NPCs and astrocytes into the preserved brain 
tissue were identified.  Also, endogenous NPCs in lesion boundary 
zone, the corpus callosum, and the thalamus were activated.  In another 
study, Hoban et al. developed a modified in situ gelling scaffold with 
collagen and poly(ethylene glycol) ether tetrasuccinimidyl glutarate 
(4S-StarPEG) to deliver rat MSCs with glial cell-derived neurotrophic 
factor (GDNF) overexpression [59]. Despite the poor survival of the 
cells, GDNF was detectable surrounding the graft site with diminished 
microglia and astrocytes recruitments in the host’s brain.  The system 
was well-tolerated and the scaffold gradually degraded in vivo.
To further influence the behavior of MSCs, collagen scaffolds are 
functionalized.  With the use of collagen-based cell-encapsulating 
scaffolds made up of interfacial polyelectrolyte complexation fibers, 
Yok et al. were able to control the spatial distribution of transplanted 
cells [52]. In response to the topographical cues presented by the fiber, 
cells seeded on the fiber surfaces showed a lower proliferation rate 
than cells encapsulated within the fibers, yet they inclined to express 
neuronal-specific markers after prolonged culture. In another recent 
study, Lee et al. investigated the response of MSCs towards electrical 
and topographic cues presented on scaffolds in culture conditions [61]. 
Incorporating low concentrations of electrical-conducting carbon 
nanotubes stimulated the expressions of neural and synaptic markers 
in rat MSCs and upregulated the secretions of nerve growth factor and 
brain-derived neurotrophic factor.
In general, collagen-based delivery improves MSC survival and 
functionalities in animal models of brain injury, resulting in amplified 
functional improvements. Further modifications in collagen-based 
systems will be beneficial to expanding the potential of collagen-based 
cell therapies for brain tissue engineering.
Neural stem/progenitor cells (NSPCs)
NSPC is another attractive candidate for collagen-based brain 
tissue engineering.  NSPCs are self-renewable multipotent stem cells 
that can differentiate into neuronal and glial cells in the CNS.  NSPCs 
can be isolated from neurogenic regions of embryonic, fetal and adult 
brain, and also be derived from ESCs, iPSCs, MSCs or immortalized 
neural stem cells (NSCs) [81,82]. Although the use of adult-derived 
NSPCs does not share the ethical and practical concerns of the use 
of embryonic or fetal cells [83], it is difficult to secure adult human 
CNS tissues for preparation of adult NSCs.  Transplanted NSPCs in 
neurological disorder models exhibit homing effects to the injured 
brain and encourage neural repair and regeneration through cell 
replacement, trophic support, immunomodulation and neuronal 
plasticity [84]. In Phase I/II clinical trials of brain tumors, PD, stable 
ischemic stroke, HD, Batten’s disease and Pelizaeus-Merzbacher 
disease, autologous NSCs and fetal brain-derived human NSCs, either 
with or without cmycER immortilization, have been applied [63,84]. 
Compared to MSCs, there are fewer reports on the in vivo performance 
of NSPCs-collagen systems in brain.
Some studies investigated the response of various sources of NSPCs 
on collagen-scaffolds in two-dimensional (2D) culture conditions. 
When exposed to mitogen, epidermal growth factor (EGF) and basic 
fibroblast growth factor (bFGF), Branvell et al. showed that embryonic 
mouse NSPCs have the highest proliferation rate whereas adult ones 
have the lowest [56]. On the other hand, postnatal NSPCs showed a 
faster differentiation process and a much higher differentiated neuronal 
percentage (70%) than both embryonic (26%) and adult (9%) NSPCs. 
This may be due to the ability of postnatal cells to adhere to collagen 
scaffold and establish paxillin-positive focal adhesions in an integrin-
dependent manner unlike adult or embryonic mouse NSPCs [85].
As for 3D scaffolds, collagen provides transplanted cells with a 
biomimetic environment that supports cell survival and formation 
of functional synapses and neuronal networks.  Bercu et al. showed 
that NSPCs survived longer in collagen scaffolds than 2D cultures for 
at least two months [8]. Embryonic rat hippocampal cells in collagen 
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showed a maintained neuronal phenotype with extensions of neuronal 
processes into the scaffold [49]. The scaffolds enabled the formation of 
a multi-level neuronal circuit with functional synapses.  O’Conner et al. 
showed that collagen matrix supported the proliferation of embryonic 
rat NSPCs in the presence of bFGF and neural cell differentiation into 
neurons and astrocytes after bFGF withdrawal [86].  Also, embryonic 
rat NSPCs cultured in collagen matrix with bFGF were able to 
derive into functional neurons, which expressed neurotransmitters, 
neurotransmitter receptors, membrane excitability and synaptic 
activity, and formed functional synapses and neuronal networks in the 
scaffold [87]. However, in vivo applications of collagen-NSPC systems 
are sometimes limited by low survival of transplanted cell at initial stage 
of implantation [16,88].  Elias et al. implanted a collagen scaffold with 
adult rat hippocampal NSPCs seeded in its open pores one week post-
injury [88]. Structural integrity of the scaffold was maintained while 
some NSPCs migrated into the surrounding brain and differentiated 
into astrocytes, endothelial cells, oligodendrocytes and possibly 
macrophages four weeks afterwards.  However, low transplanted cell 
survival and differentiation were also reported, possibly due to cytotoxic 
initial injury environment and limited differentiation stimulation in 
brain regions that were generally non-neurogenic respectively. 
To gain better control over the NSPC behaviors, some studies 
investigated the effects of scaffold functionalization.  Compared to 
collagen-coated surfaces, Wang et al. demonstrated that postnatal rat 
NSPCs cultured on collagen nanoscaffolds showed a 30% increase in 
proliferation, in which electrospun aligned scaffolds performed better 
than randomly-oriented ones [50]. Such modulated proliferation was 
mediated by cell cycle progression through the b1 integrin/MAPK 
pathway. Besides controlling topographical properties, collagen can be 
modified biochemically to form composites and to present neuroactive 
factors.  Some studies showed that the addition of ECM components 
such as hyaluronic acid (HA), laminin and fibronectin to collagen 
matrix enhanced NSPC survival and differentiation.  Although addition 
of these ECM molecules altered the gelation temperature of the cell 
delivery systems, their gelling temperatures are still physiologically 
relevant [16,56].  Brannvall et al. showed that collagen-HA scaffolds 
supported the survival, proliferation and differentiation of mice NSPCs 
into neurons, astrocytes, and oligodendrocytes in proliferative culture 
with EGF and bFGF [56].  In another study, Tate et al. transplanted 
in situ gelling collagen-laminin or collagen-fibronectin systems with 
embryonic mice NSPCs into a TBI mice model one week post-injury 
[16]. Compared to the medium delivery control, collagen groups 
showed improved cognitive function after five weeks post-implantation 
and higher NSPC survival and distribution after eight weeks. Collagen-
laminin carriers showed better results than the fibronectin group. 
To modify scaffolds with neuroactive factors, Ma et al. prepared 
genetically-modified bFGF with a fused collagen-binding polypeptide 
domain derived from mammalian collagenase, and applied it to a 
porous collagen sponge [57]. After seven days of culture, there was a 
significantly higher number of postnatal rat NSPCs in scaffolds with 
modified bFGF than those with native bFGF or phosphate-buffered 
saline control.  Another study showed that extended release of 
neuroactive factors could be achieved with collagen-fibrin cell culture 
system. Lee et al. embedded VEGF-releasing fibrin gel and murine NSC 
line C17.2 into a collagen scaffold [55]. In contrast to control systems 
without VEGF or without fibrin, this system gradually released VEGF 
for at least three days in culture and supported better cell migration and 
proliferation [55].
In short, collagen-based delivery promotes NSPC functions 
including differentiation and formation of 3D neural networks.  Since 
many of the experiments focused on in vitro investigation of NSPC-
collagen relationships, further animal studies will be needed to 
understand how the system interacts with the injury environment, and 
whether functionalized scaffolds are biocompatible and can achieve 
better therapeutic effects.  Strategies to improve the initial cell survival 
are also warranted.
Embryonic stem cells (ESCs)
ESCs are derived from the inner cell mass of the embryonic 
blastocyst.  Human ESCs (hESCs) are pluripotent and can spontaneously 
differentiate to cells in endoderm, mesoderm and ectoderm lineages. 
It is an attractive cell source because it can be maintained indefinitely 
in vitro without loss of differentiation potential [64].  However, ESC 
applications for brain injuries are potentially plagued by differentiation 
issues, tumorgensis, genetic aberrations, inflammation and rejection, 
and ethical issues [89]. One major application of ESCs in neural studies 
is to generate neuronal cell lines for drug screening, mechanistic 
investigation, or therapeutic use [83].
3D collagen scaffold influences the in vitro behavior of ESCs. 
Collagen type I stimulated the self-renewal of mouse ESCs which 
may be mediated by Bmi-1 and its downstream pathways [90]. 
When cultured within collagen-based scaffolds and differentiating 
conditions, ESCs differentiated into cells of the neural lineage and 
expressed neuronal lineage markers [91,92]. Some studies suggest that 
microarchitecture of a cell matrix played a critical role in controlling the 
overall growth and differentiation pattern of hESCs.  In collagen gels, 
rhesus monkey ESCs formed gland-like circular structures, whereas in 
collagen sponges, ESCs were scattered through the matrix or formed 
aggregates [91]. The differentiating neural tube-like structures showed 
an ependymal-like layer and neural structure with typical synapses 
[92]. Sridharan et al. demonstrated that ESCs in structureless and soft 
gelatin matrix differentiated in all three lineages, whereas in a collagen 
or a collagen-carbon nanotube (CNT) matrix with fibril structures, 
preferential development of ESCs into elongated cells with long 
filaments was observed [48]. In collagen-CNT, more than 90% of the 
cells differentiated to the ectodermal lineage at day 3, whereas for pure 
collagen, such differentiation took place at a later stage at day 6.  These 
studies showed that despite having the same chemical makeup, different 
forms of collagen scaffold had varying influences on cells.  Scaffold 
composition, architecture and designs are important factors when 
designing ESC-culture scaffolds.  Further investigations are needed to 
optimize cell-material interaction to maximize therapeutic results.
Induced Pluripotent Stem Cells (iPSCs)
iPSCs and their derivatives have great potentials in repairing 
and regenerating the injured brain.  By overexpressing a limited set 
of transgenes, such as Oct4, Sox2, c-Myc and KLF4 [93,94] or Oct4, 
Sox2, Nanog and Lin28 [95], adult somatic cells can be reprogrammed 
with pluripotency similar to ESCs. Compared to ESCs, the use and 
derivation process of iPSCs are ethically more advantageous. Although 
iPSCs retain epigenetic memory from the source tissue [96,97], they 
can differentiate into cells of all three embryonic germ layers, producing 
nearly identical progeny from neural, hepatic, and mesenchymal 
lineages [98]. As a result, patient-specific MSCs, NSPCs or other types 
of cells can be derived for autografting and potentially preventing 
immune rejection [99,100]. When applied to the brain, Wernig et al. 
showed that iPSC-derived NSPCs were able to migrate into various 
brain regions, differentiate into glia and neurons, and functionally 
integrate with the fetal mouse brain [101]. Also, the neurons derived 
promoted functional recovery in a rat PD model. 
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However, several obstacles associated with iPSCs applications for 
brain injury rescue are yet to be overcome.  For example, many human 
iPSC establishment and induction protocols are time-consuming [99] 
and have difficulties fitting the short time frame required for brain 
injury treatments.  Also, some protocols are challenged by the inability 
to generate adequate amounts of target cells for implantation [102]. 
Moreover, variations in isolation of iPSCs, differentiation and expansion 
of the derived cells exist between different iPSC cell lines [103]. For 
undifferentiated iPSCs, there exhibit risks associated with teratoma 
formation [104]. Also, abnormal gene expression in some of these 
undifferentiated cells may contribute to immune rejection by T-cell 
infiltration that led to massive necrosis in mice [105]. Optimizations 
in the protocols for reprogramming and differentiation of iPSCs are 
required to augment therapeutic efficiency and eliminate the risks of 
rejection and tumor formation.  
Current applications of iPSCs for CNS rescue include the 
establishment of neurodegenerative disease-specific cellular models, 
drug screening platforms and autologous source for cell replacement 
[100,102,106].  A recent study showed the potential of collagen-based 
scaffolds in modulating the behaviors of iPSC-derived cells. Higher 
scaffold infiltration of iPSC-derived NSPCs was observed in collagen 
scaffolds with aligned and smaller pores, resulting from preparation 
under lower freezing temperatures [107]. Also, functionalizing these 
scaffolds with laminin coating showed a dose-dependent increase in 
cell proliferation and infiltration.  Further exploration of the interaction 
between iPSCs and collagen scaffolds may shed light on the optimizing 
transplantation systems for the injured brain and cell fate control. 
Other cell candidates
Besides stem cells, behavior and response of brain neurons and 
immune-related cells in collagen systems have been explored.  East 
et al. showed that astrocytes cultured in aligned collagen scaffolds 
exhibited an enhanced neurite outgrowth [51]. Also, Yao et al. reported 
the growth and differentiation of oligodendrocyte progenitor cells 
into oligodendrocytes were supported in collagen microspheres under 
differentiation culture conditions [108]. To further functionalize 
collagen scaffolds, Sur et al. modified the matrix by adding nanofibers 
that displayed an adjustable density of laminin epitopes and hence 
bioactivity.  This composite scaffold supported the survival and normal 
functions of Granule cells and Purkinje cells, two major neuronal 
subtypes of cerebellar cortex. By tuning the laminin epitope density, 
neuronal survival and morphology can be controlled [58].  Further 
animal studies will be required to evaluate the thereapeutic efficacy of 
these cell-collagen systems.
Conclusions
Collagen is a well-studied scaffold material that can potentially 
provide a flexible platform for drug and cell delivery for repair 
and regeneration of the injured brain. Not only can it be readily 
manufactured and fabricated into various forms with desirable 
macro- and micro-structure, internal architecture and mechanical 
properties, collagen scaffolds can also be functionalized isotrophically 
or anisotropically with instructive physical, biochemical and electrical 
cues to guide the repair and regeneration process. Collagen-based cell 
transplantation demonstrated therapeutic potentials in modulating cell 
behavior and promoting repair and regeneration in preclinical studies. 
These scaffolds showed good biocompatibility and multifaceted 
rescue mechanisms, including enhanced cell survival, proliferation, 
differentiation, migration and secretion of neuroactive factors, 
which can potentially modulate the injury environment, promote 
endogenous repair mechanisms and encourage tissue replacement and 
regeneration.  
To further expand the potentials of collagen-based cell delivery, 
various issues have to be addressed.  Firstly, despite many exciting 
ideas have been proposed to optimize, modify or functionalize collagen 
scaffolds for cell delivery, majority of studies evaluated their systems 
in culture conditions and in small animal models.  Further application 
of these systems in larger animal models would be beneficial since 
they can better mimic the lesion size, complex pathophysiology of the 
injured human brain, and also the repair and regeneration mechanisms 
involved.  Secondly, studies of longer durations are warranted for a 
more thorough understanding in how transplanted and host cells 
respond to the gradually biodegrading scaffold and mediate tissue 
reorganization.  Thirdly, better guidance or control over transplanted 
and endogenous cell fates and functions in the scaffolds can potentially 
enhance cell survival and speed up graft integration, neural repair 
and regeneration process.  Also, scaffold-facilitated or cell-based drug 
delivery of therapeutics, such as anti-inflammatory and growth factors, 
that modulate the early post-injury environment may encourage higher 
survival of transplanted cells at the site of injury. Further advancement 
and understanding in the various fields of study, including stem cell 
research and technologies, collagen-based scaffold manufacturing 
techniques, mechanisms of brain injury, repair and regeneration, and 
interactions between different cell candidates, and biomaterials and 
growth signals, would direct us to further optimize, refine and enrich 
the design of cell carrying collagen-based scaffolds as biomimetic tissue 
equivalents for the injured brain.
Acknowledgement
This research was supported by the grant from the Hong Kong Research 
Grants Council (GRF #HKU773613M)
References
1. Tate C, Case C (2012) Transplanted Mesenchymal Stem Cells Aid the Injured 
Brain through Trophic Support Mechanisms. Springer, Netherlands.
2. Feigin VL, Barker-Collo S, Krishnamurthi R, Theadom A, Starkey N (2010) 
Epidemiology of ischaemic stroke and traumatic brain injury. Best Pract Res 
Clin Anaesthesiol 24: 485-494. [PubMed]
3. Mitsios N, Gaffney J, Kumar P, Krupinski J, Kumar S, et al. (2006) 
Pathophysiology of acute ischaemic stroke: an analysis of common signalling 
mechanisms and identification of new molecular targets. Pathobiology 73: 159-
175. [PubMed]
4. Werner C, Engelhard K (2007) Pathophysiology of traumatic brain injury. Br J 
Anaesth 99: 4-9. 
5. Richardson RM, Sun D, Bullock MR (2007) Neurogenesis after traumatic brain 
injury. Neurosurg Clin N Am 18: 169-181. [PubMed]
6. Eriksson PS, Perfilieva E, Bjork-Eriksson T, Alborn AM, Nordborg C, et al. 
(1998) Neurogenesis in the adult human hippocampus. Nat Med 4: 1313-1317. 
[PubMed]
7. Kernie SG, Parent JM (2010) Forebrain neurogenesis after focal Ischemic and 
traumatic brain injury. Neurobiol Dis 37: 267-274. [PubMed]
8. Bercu MM, Arien-Zakay H, Stoler D, Lecht S, Lelkes PI, et al. (2013) Enhanced 
survival and neurite network formation of human umbilical cord blood neuronal 
progenitors in three-dimensional collagen constructs. J Mol Neurosci 51: 249-
261. [PubMed]
9. Bakshi A, Keck CA, Koshkin VS, LeBold DG, Siman R, et al. (2005) Caspase-
mediated cell death predominates following engraftment of neural progenitor 
cells into traumatically injured rat brain. Brain Res 1065: 8-19. [PubMed]
10. Williams AJ, Wei HH, Dave JR, Tortella FC (2007) Acute and delayed 
neuroinflammatory response following experimental penetrating ballistic brain 
injury in the rat. J Neuroinflammation 4: 17. [PubMed]
11. Guan J, Zhu Z, Zhao RC, Xiao Z, Wu C, et al. (2013) Transplantation of human 
Citation: FSY Wong, ACY Lo (2015) Collagen-Based Scaffolds for Cell Therapies in the Injured Brain. J Stem Cell Res Ther 5: 267. doi:10.4172/2157-
7633.1000267
Page 8 of 10
Volume 5 • Issue 2 • 1000267J Stem Cell Res TherISSN: 2157-7633 JSCRT, an open access journal 
mesenchymal stem cells loaded on collagen scaffolds for the treatment of 
traumatic brain injury in rats. Biomaterials 34: 5937-5946. [PubMed]
12. Chen Z, Lu XC, Shear DA, Dave JR, Davis AR, et al. (2011) Synergism of human 
amnion-derived multipotent progenitor (AMP) cells and a collagen scaffold in 
promoting brain wound recovery: pre-clinical studies in an experimental model 
of penetrating ballistic-like brain injury. Brain Res 1368: 71-81. [PubMed]
13. Wong FS, Chan BP, Lo AC (2014) Carriers in cell-based therapies for 
neurological disorders. Int J Mol Sci 15: 10669-10723. [PubMed]
14. Lu D, Mahmood A, Qu C, Hong X, Kaplan D, et al. (2007) Collagen scaffolds 
populated with human marrow stromal cells reduce lesion volume and improve 
functional outcome after traumatic brain injury. Neurosurgery 61: 596-602. 
[PubMed]
15. Xiong Y, Qu C, Mahmood A, Liu Z, Ning R, et al. (2009) Delayed transplantation 
of human marrow stromal cell-seeded scaffolds increases transcallosal neural 
fiber length, angiogenesis, and hippocampal neuronal survival and improves 
functional outcome after traumatic brain injury in rats. Brain Res 1263: 183-
191. [PubMed]
16. Tate CC, Shear DA, Tate MC, Archer DR, Stein DG, et al. (2009) Laminin and 
fibronectin scaffolds enhance neural stem cell transplantation into the injured 
brain. J Tissue Eng Regen Med 3: 208-217. [PubMed]
17. Keilhoff G, Stang F, Wolf G, Fansa H (2003) Bio-compatibility of type I/III 
collagen matrix for peripheral nerve reconstruction. Biomaterials 24: 2779-
2787. [PubMed]
18. Udina E, Rodriguez FJ, Verdu E, Espejo M, Gold BG, et al. (2004) FK506 
enhances regeneration of axons across long peripheral nerve gaps repaired 
with collagen guides seeded with allogeneic Schwann cells. Glia 47: 120-129. 
[PubMed]
19. Stang F, Fansa H, Wolf G, Reppin M, Keilhoff G (2005) Structural parameters 
of collagen nerve grafts influence peripheral nerve regeneration. Biomaterials 
26: 3083-3091. [PubMed]
20. Phillips JB, Bunting SC, Hall SM, Brown RA (2005) Neural tissue engineering: 
a self-organizing collagen guidance conduit. Tissue Eng 11: 1611-1617. 
[PubMed]
21. Georgiou M, Bunting SC, Davies HA, Loughlin AJ, Golding JP, et al. (2013) 
Engineered neural tissue for peripheral nerve repair. Biomaterials 34: 7335-
7343. [PubMed]
22. Cholas RH, Hsu HP, Spector M (2012) The reparative response to cross-linked 
collagen-based scaffolds in a rat spinal cord gap model. Biomaterials 33: 2050-
2059. [PubMed]
23. Murakami T, Fujimoto Y, Yasunaga Y, Ishida O, Tanaka N, et al. (2003) 
Transplanted neuronal progenitor cells in a peripheral nerve gap promote nerve 
repair. Brain Res 974: 17-24. [PubMed]
24. Evans GR, Brandt K, Katz S, Chauvin P, Otto L, et al. (2002) Bioactive 
poly(L-lactic acid) conduits seeded with Schwann cells for peripheral nerve 
regeneration. Biomaterials 23: 841-848. [PubMed]
25. Emerich DF, Hammang JP, Baetge EE, Winn SR (1994) Implantation of polymer-
encapsulated human nerve growth factor-secreting fibroblasts attenuates the 
behavioral and neuropathological consequences of quinolinic acid injections 
into rodent striatum. Exp Neurol 130: 141-150. [PubMed]
26. Emerich DF, Lindner MD, Winn SR, Chen EY, Frydel BR, et al. (1996) Implants 
of encapsulated human CNTF-producing fibroblasts prevent behavioral deficits 
and striatal degeneration in a rodent model of Huntington's disease. J Neurosci 
16: 5168-5181. [PubMed]
27. Emerich DF, Winn SR, Hantraye PM, Peschanski M, Chen EY, et al. (1997) 
Protective effect of encapsulated cells producing neurotrophic factor CNTF in a 
monkey model of Huntington's disease. Nature 386: 395-399. [PubMed]
28. Emerich DF, Winn SR, Harper J, Hammang JP, Baetge EE, et al. (1994) Implants 
of polymer-encapsulated human NGF-secreting cells in the nonhuman primate: 
rescue and sprouting of degenerating cholinergic basal forebrain neurons. J 
Comp Neurol 349: 148-164. [PubMed]
29. Kordower JH, Winn SR, Liu YT, Mufson EJ, Sladek JR Jr, et al. (1994) The aged 
monkey basal forebrain: rescue and sprouting of axotomized basal forebrain 
neurons after grafts of encapsulated cells secreting human nerve growth factor. 
Proc Natl Acad Sci USA 91: 10898-10902. [PubMed]
30. Emerich DF, Winn SR, Lindner MD (1996) Continued presence of intrastriatal 
but not intraventricular polymer-encapsulated PC12 cells is required for 
alleviation of behavioral deficits in Parkinsonian rodents. Cell Transplant 5: 
589-596. [PubMed]
31. Deglon N, Heyd B, Tan SA, Joseph JM, Zurn AD, et al. (1996) Central 
nervous system delivery of recombinant ciliary neurotrophic factor by polymer 
encapsulated differentiated C2C12 myoblasts. Hum Gene Ther 7: 2135-2146. 
[PubMed]
32. Aebischer P, Schluep M, Deglon N, Joseph JM, Hirt L, et al. (1996) Intrathecal 
delivery of CNTF using encapsulated genetically modified xenogeneic cells in 
amyotrophic lateral sclerosis patients. Nat Med 2: 696-699. [PubMed]
33. Bloch J, Bachoud-Levi AC, Deglon N, Lefaucheur JP, Winkel L, et al. (2004) 
Neuroprotective gene therapy for Huntington's disease, using polymer-
encapsulated cells engineered to secrete human ciliary neurotrophic factor: 
results of a phase I study. Hum Gene Ther 15: 968-975. [PubMed]
34. Bachoud-Levi AC, Deglon N, Nguyen JP, Bloch J, Bourdet C, et al. (2000) 
Neuroprotective gene therapy for Huntington's disease using a polymer 
encapsulated BHK cell line engineered to secrete human CNTF. Hum Gene 
Ther 11: 1723-179. [PubMed]
35. Abou Neel EA, Bozec L, Knowles JC, Syed O, Mudera V, et al. (2013) Collagen-
-emerging collagen based therapies hit the patient. Adv Drug Deliv Rev 65: 
429-456. [PubMed]
36. Hulmes DJ (2002) Building collagen molecules, fibrils, and suprafibrillar 
structures. J Struct Biol 137: 2-10. [PubMed]
37. Gelse K, Poschl E, Aigner T (2003) Collagens--structure, function, and 
biosynthesis. Adv Drug Deliv Rev 55: 1531-1546. [PubMed]
38. Birk D, Brückner P (2011) Collagens, Suprastructures, and Collagen Fibril 
Assembly. Springer, Berlin Heidelberg. 
39. Kielty CM, Grant ME (2003) The Collagen Family: Structure, Assembly, and 
Organization in the Extracellular Matrix. John Wiley & Sons, Inc.
40. Parenteau-Bareil R, Gauvin R, Berthod F (2010) Collagen-Based Biomaterials 
for Tissue Engineering Applications. Materials 3: 1863-1887. 
41. Hermanns S, Klapka N, Muller HW (2001) The collagenous lesion scar--an 
obstacle for axonal regeneration in brain and spinal cord injury. Restor Neurol 
Neurosci 19: 139-148. [PubMed]
42. Silver FH, Freeman JW, Seehra GP (2003) Collagen self-assembly and the 
development of tendon mechanical properties. J Biomech 36: 1529-1553. 
[PubMed]
43. Dombi GW, Halsall HB (1985) Collagen fibril formation in the presence of 
sodium dodecyl sulphate. Biochem J 228: 551-556. [PubMed]
44. Parkinson J, Kadler KE, Brass A (1995) Simple physical model of collagen 
fibrillogenesis based on diffusion limited aggregation. J Mol Biol 247: 823-831. 
[PubMed]
45. Walters BD, Stegemann JP (2014) Strategies for directing the structure and 
function of three-dimensional collagen biomaterials across length scales. Acta 
Biomater 10: 1488-1501. [PubMed]
46. Clements IP, Munson JM, Bellamkonda RV (2013) Neuronal Tissue 
Engineering. Academic Press. 
47. Delcroix GJ, Schiller PC, Benoit JP, Montero-Menei CN (2010) Adult cell therapy 
for brain neuronal damages and the role of tissue engineering. Biomaterials 31: 
2105-2120. [PubMed]
48. Sridharan I, Kim T, Wang R (2009) Adapting collagen/CNT matrix in directing 
hESC differentiation. Biochem Biophys Res Commun 381: 508-512. [PubMed]
49. Xu T, Molnar P, Gregory C, Das M, Boland T, et al. (2009) Electrophysiological 
characterization of embryonic hippocampal neurons cultured in a 3D collagen 
hydrogel. Biomaterials 30: 4377-4383. [PubMed]
50. Wang Y, Yao M, Zhou J, Zheng W, Zhou C, et al. (2011) The promotion of 
neural progenitor cells proliferation by aligned and randomly oriented collagen 
nanofibers through beta1 integrin/MAPK signaling pathway. Biomaterials 32: 
6737-6744. [PubMed]
51. East E, de Oliveira DB, Golding JP, Phillips JB (2010) Alignment of astrocytes 
increases neuronal growth in three-dimensional collagen gels and is maintained 
following plastic compression to form a spinal cord repair conduit. Tissue Eng 
Part A 16: 3173-3184. [PubMed]
Citation: FSY Wong, ACY Lo (2015) Collagen-Based Scaffolds for Cell Therapies in the Injured Brain. J Stem Cell Res Ther 5: 267. doi:10.4172/2157-
7633.1000267
Page 9 of 10
Volume 5 • Issue 2 • 1000267J Stem Cell Res TherISSN: 2157-7633 JSCRT, an open access journal 
52. Yow SZ, Quek CH, Yim EK, Lim CT, Leong KW (2009) Collagen-based 
fibrous scaffold for spatial organization of encapsulated and seeded human 
mesenchymal stem cells. Biomaterials 30: 1133-1142. [PubMed]
53. Gu X, Ding F, Yang Y, Liu J (2011) Construction of tissue engineered nerve 
grafts and their application in peripheral nerve regeneration. Prog Neurobiol 
93: 204-230. [PubMed]
54. Lin HJ, O'Shaughnessy TJ, Kelly J, Ma W (2004) Neural stem cell differentiation 
in a cell-collagen-bioreactor culture system. Brain Res Dev Brain Res 153: 163-
173. [PubMed]
55. Lee YB, Polio S, Lee W, Dai G, Menon L, et al. (2010) Bio-printing of collagen 
and VEGF-releasing fibrin gel scaffolds for neural stem cell culture. Exp Neurol 
223: 645-652. [PubMed]
56. Brannvall K, Bergman K, Wallenquist U, Svahn S, Bowden T, et al. (2007) 
Enhanced neuronal differentiation in a three-dimensional collagen-hyaluronan 
matrix. J Neurosci Res 85: 2138-2146. [PubMed]
57. Ma F, Xiao Z, Chen B, Hou X, Han J, et al. (2014) Accelerating proliferation of 
neural stem/progenitor cells in collagen sponges immobilized with engineered 
basic fibroblast growth factor for nervous system tissue engineering. 
Biomacromolecules 15: 1062-1068. [PubMed]
58. Sur S, Pashuck ET, Guler MO, Ito M, Stupp SI, et al. (2012) A hybrid nanofiber 
matrix to control the survival and maturation of brain neurons. Biomaterials 33: 
545-555. [PubMed]
59. Hoban DB, Newland B, Moloney TC, Howard L, Pandit A, et al. (2013) The 
reduction in immunogenicity of neurotrophin overexpressing stem cells after 
intra-striatal transplantation by encapsulation in an in situ gelling collagen 
hydrogel. Biomaterials 34: 9420-9429. [PubMed]
60. Willerth SM, Sakiyama-Elbert SE (2007) Approaches to neural tissue 
engineering using scaffolds for drug delivery. Adv Drug Deliv Rev 59: 325-338. 
[PubMed]
61. Lee JH, Lee JY, Yang SH, Lee EJ, Kim HW (2014) Carbon nanotube-collagen 
three-dimensional culture of mesenchymal stem cells promotes expression of 
neural phenotypes and secretion of neurotrophic factors. Acta Biomater 10: 
4425-4436. [PubMed]
62. Ghasemi-Mobarakeh L, Prabhakaran MP, Morshed M, Nasr-Esfahani MH, 
Baharvand H, et al. (2011) Application of conductive polymers, scaffolds and 
electrical stimulation for nerve tissue engineering. J Tissue Eng Regen Med 5: 
e17-35. [PubMed]
63. Aboody K, Capela A, Niazi N, Stern JH, Temple S (2011) Translating stem cell 
studies to the clinic for CNS repair: current state of the art and the need for a 
Rosetta stone. Neuron 70: 597-613. [PubMed]
64. Tuan RS, Boland G, Tuli R (2003) Adult mesenchymal stem cells and cell-
based tissue engineering. Arthritis Res Ther 5: 32-45. [PubMed]
65. Glavaski-Joksimovic A, Bohn MC (2013) Mesenchymal stem cells and 
neuroregeneration in Parkinson's disease. Exp Neurol 247: 25-38. [PubMed]
66. Hass R, Kasper C, Bohm S, Jacobs R (2011) Different populations and sources 
of human mesenchymal stem cells (MSC): A comparison of adult and neonatal 
tissue-derived MSC. Cell Commun Signal 9: 12. [PubMed]
67. Waddington RJ, Youde SJ, Lee CP, Sloan AJ (2009) Isolation of distinct 
progenitor stem cell populations from dental pulp. Cells Tissues Organs 189: 
268-274. [PubMed]
68. Alhadlaq A, Mao JJ (2004) Mesenchymal stem cells: isolation and therapeutics. 
Stem Cells Dev 13: 436-448. [PubMed]
69. Caplan AI, Dennis JE (2006) Mesenchymal stem cells as trophic mediators. J 
Cell Biochem 98: 1076-1084. [PubMed]
70. Yagi H, Soto-Gutierrez A, Parekkadan B, Kitagawa Y, Tompkins RG, et al. 
(2010) Mesenchymal stem cells: Mechanisms of immunomodulation and 
homing. Cell Transplant 19: 667-679. [PubMed]
71. Parr AM, Tator CH, Keating A (2007) Bone marrow-derived mesenchymal 
stromal cells for the repair of central nervous system injury. Bone Marrow 
Transplant 40: 609-619. [PubMed]
72. Li Y, Chopp M (2009) Marrow stromal cell transplantation in stroke and 
traumatic brain injury. Neurosci Lett 456: 120-123. [PubMed]
73. Nakada A, Fukuda S, Ichihara S, Sato T, Itoi S, et al. (2009) Regeneration of 
central nervous tissue using a collagen scaffold and adipose-derived stromal 
cells. Cells Tissues Organs 190: 326-335. [PubMed]
74. Cox CS Jr, Baumgartner JE, Harting MT, Worth LL, Walker PA, et al. (2011) 
Autologous bone marrow mononuclear cell therapy for severe traumatic brain 
injury in children. Neurosurgery 68: 588-600. [PubMed]
75. Venkataramana NK, Kumar SK, Balaraju S, Radhakrishnan RC, Bansal A, et 
al. (2010) Open-labeled study of unilateral autologous bone-marrow-derived 
mesenchymal stem cell transplantation in Parkinson's disease. Transl Res 155: 
62-70. [PubMed]
76. Qu C, Mahmood A, Liu XS, Xiong Y, Wang L, et al. (2011) The treatment of TBI 
with human marrow stromal cells impregnated into collagen scaffold: functional 
outcome and gene expression profile. Brain Res 1371: 129-139. [PubMed]
77. Mahmood A, Qu C, Ning R, Wu H, Goussev A, et al. (2011) Treatment of TBI with 
collagen scaffolds and human marrow stromal cells increases the expression of 
tissue plasminogen activator. J Neurotrauma 28: 1199-1207. [PubMed]
78. Mahmood A, Wu H, Qu C, Mahmood S, Xiong Y, et al. (2014) Down-regulation 
of Nogo-A by collagen scaffolds impregnated with bone marrow stromal cell 
treatment after traumatic brain injury promotes axonal regeneration in rats. 
Brain Res 1542: 41-48. [PubMed]
79. Mahmood A, Wu H, Qu C, Mahmood S, Xiong Y, et al. (2014) Suppression 
of neurocan and enhancement of axonal density in rats after treatment of 
traumatic brain injury with scaffolds impregnated with bone marrow stromal 
cells. J Neurosurg 120: 1147-1155. [PubMed]
80. Qu C, Xiong Y, Mahmood A, Kaplan DL, Goussev A, et al. (2009) Treatment 
of traumatic brain injury in mice with bone marrow stromal cell-impregnated 
collagen scaffolds. J Neurosurg 111: 658-665. [PubMed]
81. Kim SU, Lee HJ, Kim YB (2013) Neural stem cell-based treatment for 
neurodegenerative diseases. Neuropathology 33: 491-504. [PubMed]
82. Bithell A, Williams BP (2005) Neural stem cells and cell replacement therapy: 
making the right cells. Clin Sci (Lond) 108: 13-22. [PubMed]
83. Kalladka D, Muir KW (2014) Brain repair: cell therapy in stroke. Stem Cells 
Cloning 7: 31-44. [PubMed]
84. De Feo D, Merlini A, Laterza C, Martino G (2012) Neural stem cell transplantation 
in central nervous system disorders: from cell replacement to neuroprotection. 
Curr Opin Neurol 25: 322-333. [PubMed]
85. Bergstrom T, Holmqvist K, Tararuk T, Johansson S, Forsberg-Nilsson K (2014) 
Developmentally regulated collagen/integrin interactions confer adhesive 
properties to early postnatal neural stem cells. Biochim Biophys Acta 1840: 
2526-2532. [PubMed]
86. O'Connor SM, Stenger DA, Shaffer KM, Maric D, Barker JL, et al. (2000) 
Primary neural precursor cell expansion, differentiation and cytosolic Ca(2+) 
response in three-dimensional collagen gel. J Neurosci Methods 102: 187-195. 
[PubMed]
87. Ma W, Fitzgerald W, Liu QY, O'Shaughnessy TJ, Maric D, et al. (2004) CNS 
stem and progenitor cell differentiation into functional neuronal circuits in three-
dimensional collagen gels. Exp Neurol 190: 276-288. [PubMed]
88. Elias PZ, Spector M (2012) Implantation of a collagen scaffold seeded with 
adult rat hippocampal progenitors in a rat model of penetrating brain injury. J 
Neurosci Methods 209: 199-211. [PubMed]
89. Li JY, Christophersen NS, Hall V, Soulet D, Brundin P (2008) Critical issues of 
clinical human embryonic stem cell therapy for brain repair. Trends Neurosci 
31: 146-153. [PubMed]
90. Suh HN, Han HJ (2011) Collagen I regulates the self-renewal of mouse 
embryonic stem cells through alpha2beta1 integrin- and DDR1-dependent Bmi-
1. J Cell Physiol 226: 3422-3432. [PubMed]
91. Chen SS, Revoltella RP, Papini S, Michelini M, Fitzgerald W, et al. (2003) 
Multilineage differentiation of rhesus monkey embryonic stem cells in three-
dimensional culture systems. Stem cells 21: 281-295. [PubMed]
92. Baharvand H, Mehrjardi NZ, Hatami M, Kiani S, Rao M, et al. (2007) Neural 
differentiation from human embryonic stem cells in a defined adherent culture 
condition. Int J Dev Biol 51: 371-378. [PubMed]
93. Park IH, Zhao R, West JA, Yabuuchi A, Huo H, et al. (2008) Reprogramming of 
human somatic cells to pluripotency with defined factors. Nature 451: 141-146. 
[PubMed]
94. Takahashi K, Tanabe K, Ohnuki M, Narita M, Ichisaka T, et al. (2007) Induction 
of pluripotent stem cells from adult human fibroblasts by defined factors. Cell 
131: 861-872. [PubMed]
Citation: FSY Wong, ACY Lo (2015) Collagen-Based Scaffolds for Cell Therapies in the Injured Brain. J Stem Cell Res Ther 5: 267. doi:10.4172/2157-
7633.1000267
Page 10 of 10
Volume 5 • Issue 2 • 1000267J Stem Cell Res TherISSN: 2157-7633 JSCRT, an open access journal 
95. Yu J, Vodyanik MA, Smuga-Otto K, Antosiewicz-Bourget J, Frane JL, et al. 
(2007) Induced pluripotent stem cell lines derived from human somatic cells. 
Science 318: 1917-1920. [PubMed]
96. Kim DS, Lee JS, Leem JW, Huh YJ, Kim JY, et al. (2010) Robust enhancement 
of neural differentiation from human ES and iPS cells regardless of their innate 
difference in differentiation propensity. Stem Cell Rev 6: 270-281. [PubMed]
97. Chin MH, Mason MJ, Xie W, Volinia S, Singer M, et al. (2009) Induced 
pluripotent stem cells and embryonic stem cells are distinguished by gene 
expression signatures. Cell Stem Cell 5: 111-123. [PubMed]
98. Patterson M, Chan DN, Ha I, Case D, Cui Y, et al. (2012) Defining the nature of 
human pluripotent stem cell progeny. Cell Res 22: 178-193. 
99. Matsui T, Akamatsu W, Nakamura M, Okano H (2014) Regeneration of the 
damaged central nervous system through reprogramming technology: basic 
concepts and potential application for cell replacement therapy. Exp Neurol 
260: 12-18. [PubMed]
100. Gao A, Peng Y, Deng Y, Qing H (2013) Potential therapeutic applications 
of differentiated induced pluripotent stem cells (iPSCs) in the treatment of 
neurodegenerative diseases. Neuroscience 228: 47-59. [PubMed]
101. Wernig M, Zhao J-P, Pruszak J, Hedlund E, Fu D, et al. (2008) Neurons 
derived from reprogrammed fibroblasts functionally integrate into the fetal 
brain and improve symptoms of rats with Parkinson's disease. Proc Natl Acad 
Sci USA 105: 5856-5861. [PubMed]
102. Mattis VB, Svendsen CN (2011) Induced pluripotent stem cells: a new 
revolution for clinical neurology? Lancet Neurol 10: 383-394. [PubMed]
103. Wang A, Tang Z, Park IH, Zhu Y, Patel S, et al. (2011) Induced pluripotent stem 
cells for neural tissue engineering. Biomaterials 32: 5023-5032. [PubMed]
104. Miura K, Okada Y, Aoi T, Okada A, Takahashi K, et al. (2009) Variation in 
the safety of induced pluripotent stem cell lines. Nat Biotech 27: 743-745. 
[PubMed]
105. Zhao T, Zhang Z-N, Rong Z, Xu Y (2011) Immunogenicity of induced pluripotent 
stem cells. Nature 474: 212-215. [PubMed]
106. Jung Y-W, Hysolli E, Kim K-Y, Tanaka Y, Park I-H (2012) Human induced 
pluripotent stem cells and neurodegenerative disease: prospects for novel 
therapies. Curr Opin Neurol 25: 125-130. [PubMed]
107. Khayyatan F, Nemati S, Kiani S, Hojjati Emami S, et al. (2014) Behaviour of 
human induced pluripotent stem cell-derived neural progenitors on collagen 
scaffolds varied in freezing temperature and laminin concentration. Cell J 16: 
53-62. [PubMed]
108. Yao L, Phan F, Li Y (2013) Collagen microsphere serving as a cell carrier 
supports oligodendrocyte progenitor cell growth and differentiation for neurite 
myelination in vitro. Stem Cell Res Ther 4: 109. [PubMed]
Citation: FSY Wong, ACY Lo (2015) Collagen-Based Scaffolds for Cell 
Therapies in the Injured Brain. J Stem Cell Res Ther 5: 267. doi:10.4172/2157-
7633.1000267
SuBMI1t your next manuscript and get advantages of 
OMICS Group suBMI1ssions
Unique features:
• User friendly/feasible website-translation of your paper to 50 world’s leading languages
• Audio Version of published paper
• Digital articles to share and explore
Special features:
• 400 Open Access Journals
• 30,000 editorial team
• 21 days rapid review process
• Quality and quick editorial, review and publication processing
• Indexing at Pubmed (partial), Scopus, EBSCO, Index Copernicus and Google Scholar etc
• Sharing Option: Social Networking Enabled
• Authors, Reviewers and Editors rewarded with online Scientific Credits
• Better discount for your subsequent articles
SuBMI1t your manuscript at: http://www.omicsonline.org/suBMI1ssion
